[en] Full text: Adriamycin is a commonly used chemotherapeutic agent in patients with cancer, having cardiotoxicity as its main side effect. This effect is through generation of free radicals and mitochondrial damage. Adriamycin produces hypoxia and decreases synthesis of ATP molecules by aerobic oxidation. To meet this energy synthesis-demand deficit, glycolysis is favored. Hence such 'injured' myocardial cells switch over to glucose as their main source of energy. Neuregulins are a family of growth factors which exert cytoprotection in Adriamycin treated myocytes. Increased glycolysis is one of the downregulatory signal in this pathway. (¹⁸F)FDG is concentrated in the myocardial cells via Glut receptors and acts as a marker of glucose metabolism. Based on the above facts, we decided to study the effects of adriamycin on glucose metabolism in myocardium in vivo, with the help of ¹⁸F-FDG PET. Aim: To observe (¹⁸F)FDG myocardial uptake in patients of lymphoma undergoing treatment with Adriamycin. Materials and Methods: A retrospective analysis was done from the data of (¹⁸F)FDG PET scan of lymphoma patients who have completed anthracycline chemotherapy and underwent the said scan for their routine evaluation. The cardiac processing was done separately and a polar map (Bulls eye) generated from the SA slices of the myocardial tracer activity of these patients. Mean SUV value was calculated for the above-mentioned map. This mean SUV calculated in both pre- and post-chemotherapy scans was compared and analysed. Results: 18 patients (16M and 2F with mean age: 32.66 ± 14.81 years) of lymphoma who underwent pre- and post-doxorubicin therapy formed part of the study. The mean dose of doxorubicin received was 227.7 ± 116.59 mg/M² of BSA. Three different groups were identified among these cases, 1) Group A showing increase in cardiac FDG uptake in post doxorubicin PET scan. Mean dose of doxorubicin received was 256.25 mg/m² of BSA. 2) Group B showing fall in myocardial FDG uptake in post doxorubicin PET scan as compared to pre therapy scan. Mean dose of doxorubicin received was 137.5 mg/m² of BSA. 3) Group C, did not show significant FDG uptake in pre as well as post doxorubicin PET scans. Mean dose of doxorubicin received was 250 mg/m² of body surface area (BSA). Preliminary results did not show any correlation between the dose of doxorubicin administered and myocardial (¹⁸F)FDG concentration. Conclusion: The lymphoma patients treated with doxorubicin demonstrated variable dose dependent effects of glucose utilization in the myocardium using FDG-PET. However, prospective study with larger number of patients and patients receiving higher dose of doxorubicin could be worthwhile in ascertaining the metabolic changes associated with the drug and its effect on substrate metabolism of the heart